Subject: AEPP Adds Industry Vets Bringing Clinical and Manufacturing Expertise

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
AEPP Adds Industry Vets Bringing Clinical and Manufacturing Expertise
Hot Stock to WatchHot Stock to Watch

Company: Oncolix, Inc. (Pink Sheets: AEPP)


Last:

Price: 0.06

Change (%): + 0.0012 (2.04)

Volume: 13,788
AEPP Chart

Oncolix Appoints Two Members to Its Board of Directors

Board Members bring Clinical and Manufacturing Expertise to Clinical-Stage Biopharmaceutical Company

Independent Board Member Appointment Step toward NASDAQ Listing Objective

HOUSTON, Oct. 04, 2017 (GLOBE NEWSWIRE) - Oncolix, Inc. (OTC PINK:AEPP) (the “Company”), a biotechnology company focused on gynecological cancers, announced on October 4, 2017, the Board of Directors voted to increase the number of directors to three from the current two and elected Jerry R. Youkey, M.D., and Dale Zajicek to serve on the Company’s Board of Directors. Mr. Zajicek is the first independent board member of the company.

Dr. Youkey and Mr. Zajicek have served as Directors of the Company’s wholly owned subsidiary, Oncolix, Inc., (a Delaware corporation) since 2007. In connection with such action, J. Donald Payne resigned as a director of the Company but continues to serve as its secretary. Michael T. Redman, chief executive officer of Oncolix, continues to serve as the Company’s third director. The term of all directors continues until their reelection or replacement by action of the stockholders of the Company.

“Following the completion of the merger in August 2017, we have been focused on building an innovative biopharmaceutical company with the objective of developing and launching our lead candidate, Prolanta™, to treat ovarian and other cancers,” said Michael T. Redman, president and CEO of Oncolix. “Part of that process is to build the public company infrastructure that will first fulfill the OTC-QB requirement to have at least two independent directors and, ultimately, to qualify for a NASDAQ listing. The appointment of Mr. Zajicek as an independent director assists with that objective. In addition, both appointees have already made valuable contributions and will be instrumental in adding additional world-class board members. Oncolix will soon be adding an independent fourth director, which will also fulfill the OTC-QB requirement.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks